Pages that link to "Q44825601"

The following pages link to Amplified in breast cancer 1 in human epidermal growth factor receptor - positive tumors of tamoxifen-treated breast cancer patients (Q44825601):

Displaying 50 items.

• Oral exposure to bisphenol a increases dimethylbenzanthracene-induced mammary cancer in rats (Q24657393) (← links)
• Identification of SRC3/AIB1 as a Preferred Coactivator for Hormone-activated Androgen Receptor (Q27659041) (← links)
• SRC-3 Has a Role in Cancer Other Than as a Nuclear Receptor Coactivator (Q27687681) (← links)
• Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial (Q27851630) (← links)
• Prognostic relevance of AIB1 (NCoA3) amplification and overexpression in breast cancer (Q27852024) (← links)
• Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies (Q28072897) (← links)
• Extranuclear coactivator signaling confers insensitivity to tamoxifen (Q28246263) (← links)
• Prior Adjuvant Tamoxifen Treatment in Breast Cancer Is Linked to Increased AIB1 and HER2 Expression in Metachronous Contralateral Breast Cancer (Q28550645) (← links)
• Tamoxifen resistance in early breast cancer: statistical modelling of tissue markers to improve risk prediction (Q33847811) (← links)
• Cooperative activation of cyclin D1 and progesterone receptor gene expression by the SRC-3 coactivator and SMRT corepressor (Q33874323) (← links)
• In utero exposure to bisphenol A shifts the window of susceptibility for mammary carcinogenesis in the rat (Q34282898) (← links)
• The role and regulation of the nuclear receptor co-activator AIB1 in breast cancer. (Q34286419) (← links)
• The epidermal growth factor receptor family in breast cancer (Q34363400) (← links)
• HER2 Signaling Drives DNA Anabolism and Proliferation through SRC-3 Phosphorylation and E2F1-Regulated Genes (Q34511826) (← links)
• SRC-3 coactivator regulates cell resistance to cytotoxic stress via TRAF4-mediated p53 destabilization (Q34579190) (← links)
• The potential role of estrogen receptors and the SRC family as targets for the treatment of breast cancer (Q34982010) (← links)
• Steroid receptor coactivators 1, 2, and 3: Critical regulators of nuclear receptor activity and steroid receptor modulator (SRM)-based cancer therapy (Q35456938) (← links)
• Minireview: Steroid Receptor Coactivator-3: A Multifarious Coregulator in Mammary Gland Metastasis (Q35558470) (← links)
• Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression (Q35786712) (← links)
• The changing role of ER in endocrine resistance (Q36336601) (← links)
• The role of AIB1 in breast cancer (Q36423878) (← links)
• Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance. (Q36589865) (← links)
• Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients (Q36643014) (← links)
• The nuclear receptor coactivator amplified in breast cancer-1 is required for Neu (ErbB2/HER2) activation, signaling, and mammary tumorigenesis in mice. (Q36811130) (← links)
• Epidermal growth factor receptor tyrosine phosphorylation and signaling controlled by a nuclear receptor coactivator, amplified in breast cancer 1. (Q36850793) (← links)
• Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance (Q36860992) (← links)
• Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance (Q36896155) (← links)
• Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer (Q37032861) (← links)
• Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer (Q37156496) (← links)
• Her2 cross talk and therapeutic resistance in breast cancer (Q37175204) (← links)
• Antitumor agents. 266. Design, synthesis, and biological evaluation of novel 2-(furan-2-yl)naphthalen-1-ol derivatives as potent and selective antibreast cancer agents. (Q37368121) (← links)
• Bufalin is a potent small-molecule inhibitor of the steroid receptor coactivators SRC-3 and SRC-1 (Q37626561) (← links)
• The role of SRC-3 in human breast cancer (Q37660904) (← links)
• The roles and action mechanisms of p160/SRC coactivators and the ANCCA coregulator in cancer (Q37726336) (← links)
• Artificial intelligence techniques for colorectal cancer drug metabolism: ontology and complex network. (Q37743545) (← links)
• Drug discovery and design for complex diseases through QSAR computational methods. (Q37774003) (← links)
• Cracking the Estrogen Receptor's Posttranslational Code in Breast Tumors (Q37890710) (← links)
• Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy? (Q38028797) (← links)
• Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer (Q38416045) (← links)
• Proximity ligation assays for isoform-specific Akt activation in breast cancer identify activated Akt1 as a driver of progression (Q38486355) (← links)
• Alteration of Y-box binding protein-1 expression modifies the response to endocrine therapy in estrogen receptor-positive breast cancer (Q39485529) (← links)
• Transient over-expression of estrogen receptor-α in breast cancer cells promotes cell survival and estrogen-independent growth (Q39664547) (← links)
• Virtual tissue microarrays: a novel and viable approach to optimizing tissue microarrays for biomarker research applied to ductal carcinoma in situ (Q40152768) (← links)
• The role of AIB1 and PAX2 in primary breast cancer: validation of AIB1 as a negative prognostic factor (Q43951760) (← links)
• AIB1 is a predictive factor for tamoxifen response in premenopausal women. (Q45921492) (← links)
• Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98. (Q47143778) (← links)
• Estrogen receptor alpha/beta, AIB1, and TIF2 in colorectal carcinogenesis: do coregulators have prognostic significance? (Q51836381) (← links)
• GSK3β and cyclin D1 expression predicts outcome in early breast cancer patients. (Q53145438) (← links)
• The p160 ER co-regulators predict outcome in ER negative breast cancer (Q53751223) (← links)
• The effects of bufadienolides on HER2 overexpressing breast cancer cells. (Q53805460) (← links)